Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies.

Gufford BT, Ainslie GR, White JR Jr, Layton ME, Padowski JM, Pollack GM, Paine MF.

Clin Transl Sci. 2017 Sep;10(5):380-386. doi: 10.1111/cts.12473. Epub 2017 May 23.

2.

Influence of enterohepatic recycling on the time course of brain-to-blood partitioning of valproic acid in rats.

Padowski JM, Pollack GM.

Drug Metab Dispos. 2012 Sep;40(9):1846-53. doi: 10.1124/dmd.112.045500. Epub 2012 Jun 19.

3.

A modified team-based learning physiology course.

Persky AM, Pollack GM.

Am J Pharm Educ. 2011 Dec 15;75(10):204. doi: 10.5688/ajpe7510204.

4.

Influence of time to achieve substrate distribution equilibrium between brain tissue and blood on quantitation of the blood-brain barrier P-glycoprotein effect.

Padowski JM, Pollack GM.

Brain Res. 2011 Dec 2;1426:1-17. doi: 10.1016/j.brainres.2011.10.009. Epub 2011 Oct 8.

PMID:
22036081
5.

The influence of distributional kinetics into a peripheral compartment on the pharmacokinetics of substrate partitioning between blood and brain tissue.

Padowski JM, Pollack GM.

J Pharmacokinet Pharmacodyn. 2011 Dec;38(6):743-67. doi: 10.1007/s10928-011-9218-0. Epub 2011 Oct 9.

PMID:
21983688
6.

Mechanisms underlying differences in systemic exposure of structurally similar active metabolites: comparison of two preclinical hepatic models.

Yan GZ, Brouwer KL, Pollack GM, Wang MZ, Tidwell RR, Hall JE, Paine MF.

J Pharmacol Exp Ther. 2011 May;337(2):503-12. doi: 10.1124/jpet.110.177220. Epub 2011 Feb 14.

7.

Transforming a large-class lecture course to a smaller-group interactive course.

Persky AM, Pollack GM.

Am J Pharm Educ. 2010 Nov 10;74(9):170.

8.

Roles of innovation in education delivery.

Blouin RA, Riffee WH, Robinson ET, Beck DE, Green C, Joyner PU, Persky AM, Pollack GM.

Am J Pharm Educ. 2009 Dec 17;73(8):154. Review.

9.
10.

Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation.

Padowski JM, Pollack GM.

Methods Mol Biol. 2010;596:359-84. doi: 10.1007/978-1-60761-416-6_16. Review.

PMID:
19949932
11.

A hybrid jigsaw approach to teaching renal clearance concepts.

Persky AM, Pollack GM.

Am J Pharm Educ. 2009 May 27;73(3):49.

12.

Regional differences in capillary density, perfusion rate, and P-glycoprotein activity: a quantitative analysis of regional drug exposure in the brain.

Zhao R, Pollack GM.

Biochem Pharmacol. 2009 Oct 15;78(8):1052-9. doi: 10.1016/j.bcp.2009.06.001. Epub 2009 Jun 10.

PMID:
19523457
13.

Sex-dependent disposition of acetaminophen sulfate and glucuronide in the in situ perfused mouse liver.

Lee JK, Abe K, Bridges AS, Patel NJ, Raub TJ, Pollack GM, Brouwer KL.

Drug Metab Dispos. 2009 Sep;37(9):1916-21. doi: 10.1124/dmd.109.026815. Epub 2009 Jun 1.

14.
15.

Assessment of blood-brain barrier permeability using the in situ mouse brain perfusion technique.

Zhao R, Kalvass JC, Pollack GM.

Pharm Res. 2009 Jul;26(7):1657-64. doi: 10.1007/s11095-009-9876-4. Epub 2009 Apr 22.

PMID:
19384470
16.

Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier.

Zhao R, Raub TJ, Sawada GA, Kasper SC, Bacon JA, Bridges AS, Pollack GM.

Drug Metab Dispos. 2009 Jun;37(6):1251-8. doi: 10.1124/dmd.108.025064. Epub 2009 Mar 9.

17.

Training clinical pharmaceutical scientists in today's highly competitive times: it's time to commit to change.

Blouin RA, Pollack GM.

Pharmacotherapy. 2009 Feb;29(2):134-6; discussion 136-7. doi: 10.1592/phco.29.2.134. No abstract available.

PMID:
19170583
18.

Fexofenadine brain exposure and the influence of blood-brain barrier P-glycoprotein after fexofenadine and terfenadine administration.

Zhao R, Kalvass JC, Yanni SB, Bridges AS, Pollack GM.

Drug Metab Dispos. 2009 Mar;37(3):529-35. doi: 10.1124/dmd.107.019893. Epub 2008 Dec 29.

19.

Relationship between drug/metabolite exposure and impairment of excretory transport function.

Zamek-Gliszczynski MJ, Kalvass JC, Pollack GM, Brouwer KL.

Drug Metab Dispos. 2009 Feb;37(2):386-90. doi: 10.1124/dmd.108.023648. Epub 2008 Nov 20.

20.
21.

Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.

Dumas EO, Pollack GM.

AAPS J. 2008 Dec;10(4):537-51. doi: 10.1208/s12248-008-9056-1. Epub 2008 Nov 7.

22.

Effect of albumin on the biliary clearance of compounds in sandwich-cultured rat hepatocytes.

Wolf KK, Brouwer KR, Pollack GM, Brouwer KL.

Drug Metab Dispos. 2008 Oct;36(10):2086-92. doi: 10.1124/dmd.108.020842. Epub 2008 Jul 24.

23.

Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies.

Ghibellini G, Leslie EM, Pollack GM, Brouwer KL.

Pharm Res. 2008 Aug;25(8):1851-60. doi: 10.1007/s11095-008-9597-0. Epub 2008 May 30.

24.

Preparing for a Renaissance in pharmacy education: the need, opportunity, and capacity for change.

Blouin RA, Joyner PU, Pollack GM.

Am J Pharm Educ. 2008 Apr 15;72(2):42. No abstract available.

25.

Coordinated nuclear receptor regulation of the efflux transporter, Mrp2, and the phase-II metabolizing enzyme, GSTpi, at the blood-brain barrier.

Bauer B, Hartz AM, Lucking JR, Yang X, Pollack GM, Miller DS.

J Cereb Blood Flow Metab. 2008 Jun;28(6):1222-34. doi: 10.1038/jcbfm.2008.16. Epub 2008 Mar 19.

PMID:
18349876
26.

Good outcome development is good science.

Persky AM, Cox WC, Deloatch K, Pollack GM.

Am J Pharm Educ. 2007 Aug 15;71(4):74. No abstract available.

27.

Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data.

Kalvass JC, Olson ER, Cassidy MP, Selley DE, Pollack GM.

J Pharmacol Exp Ther. 2007 Oct;323(1):346-55. Epub 2007 Jul 23.

PMID:
17646430
28.

Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice.

Tian X, Li J, Zamek-Gliszczynski MJ, Bridges AS, Zhang P, Patel NJ, Raub TJ, Pollack GM, Brouwer KL.

Antimicrob Agents Chemother. 2007 Sep;51(9):3230-4. Epub 2007 Jun 18.

32.

In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation.

Bauer B, Yang X, Hartz AM, Olson ER, Zhao R, Kalvass JC, Pollack GM, Miller DS.

Mol Pharmacol. 2006 Oct;70(4):1212-9. Epub 2006 Jul 12.

PMID:
16837625
34.

Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes.

Turncliff RZ, Hoffmaster KA, Kalvass JC, Pollack GM, Brouwer KL.

J Pharmacol Exp Ther. 2006 Aug;318(2):881-9. Epub 2006 May 11.

PMID:
16690724
35.

Modulation of hepatic canalicular or basolateral transport proteins alters hepatobiliary disposition of a model organic anion in the isolated perfused rat liver.

Chandra P, Johnson BM, Zhang P, Pollack GM, Brouwer KL.

Drug Metab Dispos. 2005 Aug;33(8):1238-43. Epub 2005 May 20.

PMID:
15908472
36.

Nasal drug administration: potential for targeted central nervous system delivery.

Graff CL, Pollack GM.

J Pharm Sci. 2005 Jun;94(6):1187-95. Review.

PMID:
15858850
37.

Pharmacokinetics of substrate uptake and distribution in murine brain after nasal instillation.

Graff CL, Zhao R, Pollack GM.

Pharm Res. 2005 Feb;22(2):235-44.

PMID:
15783071
38.

Functional evidence for P-glycoprotein at the nose-brain barrier.

Graff CL, Pollack GM.

Pharm Res. 2005 Jan;22(1):86-93.

PMID:
15771234
39.

Neuronal nitric oxide modulates morphine antinociceptive tolerance by enhancing constitutive activity of the mu-opioid receptor.

Heinzen EL, Booth RG, Pollack GM.

Biochem Pharmacol. 2005 Feb 15;69(4):679-88. Epub 2005 Jan 7.

PMID:
15670586
40.

Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice.

Kalvass JC, Graff CL, Pollack GM.

Pharm Res. 2004 Oct;21(10):1867-70.

PMID:
15553234
41.

Multiple transport systems mediate the hepatic uptake and biliary excretion of the metabolically stable opioid peptide [D-penicillamine2,5]enkephalin.

Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, Brouwer KL.

Drug Metab Dispos. 2005 Feb;33(2):287-93. Epub 2004 Nov 4.

PMID:
15528320
42.
43.

Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues.

Matheny CJ, Ali RY, Yang X, Pollack GM.

Drug Metab Dispos. 2004 Sep;32(9):1008-14.

PMID:
15319343
44.

Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems.

Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, Brouwer KL.

J Pharmacol Exp Ther. 2004 Dec;311(3):1203-10. Epub 2004 Aug 9.

PMID:
15302892
45.

Modelling the cardiovascular effects of ephedrine.

Persky AM, Berry NS, Pollack GM, Brouwer KL.

Br J Clin Pharmacol. 2004 May;57(5):552-62.

46.

Use of an electrochemical nitric oxide sensor to detect neuronal nitric oxide production in conscious, unrestrained rats.

Heinzen EL, Pollack GM.

J Pharmacol Toxicol Methods. 2002 Nov-Dec;48(3):139-46.

PMID:
14986862
47.

Drug transport at the blood-brain barrier and the choroid plexus.

Graff CL, Pollack GM.

Curr Drug Metab. 2004 Feb;5(1):95-108. Review.

PMID:
14965253
48.

The development of morphine antinociceptive tolerance in nitric oxide synthase-deficient mice.

Heinzen EL, Pollack GM.

Biochem Pharmacol. 2004 Feb 15;67(4):735-41.

PMID:
14757173
49.

Variable modulation of opioid brain uptake by P-glycoprotein in mice.

Dagenais C, Graff CL, Pollack GM.

Biochem Pharmacol. 2004 Jan 15;67(2):269-76.

PMID:
14698039
50.

Supplemental Content

Loading ...
Support Center